NCT05671653View on ClinicalTrials.gov

A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range

PHASE1TerminatedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 19, 2023

Primary Completion Date

November 3, 2023

Study Completion Date

November 3, 2023

Conditions
Obesity
Interventions
DRUG

PF-07081532

Experimental oral GLP-1 drug

DRUG

Semaglutide

Approved and marketed GLP-1 drug for subcutaneous injection.

Trial Locations (1)

92801

Anaheim Clinical Trials, LLC, Anaheim

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05671653 - A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range | Biotech Hunter | Biotech Hunter